Drug-eluting stenting for Wingspan in-stent restenosis of vertebral artery / 中国脑血管病杂志

ABSTRACT

Objective: To investigate the feasibility and safety of drug-eluting stenting for Wingspan in-stent restenosis Methods: Firebird drug-eluting stenting was used to treat two patients with Wingspan in-stent restenosis (localized restenosis >70% at vertebral artery V4 segment). One of them was a symptomatic case, and the other had contralateral vertebral artery occlusion and bilateral posterior communicating artery hypoplasia. The stents passed through the restenotic site, and they were released under the pressure of 911.93 to 1013.25 kPa, maintaining for 15 seconds. Results: All the stents were successfully released in place. Angiography showed that there was no significant residual stenosis immediately after the procedure. There was no discomfort in patients after the procedure. The patient's preoperative symptom of repeated vertigo attacks was disappeared. No clinical ischemic event occurred in the two patients after following up for more than 6 months. Six months after the restenting, DSA re-examination showed that there was no significant restenosis in one patient. Conclusion: Using drug-eluting stents for in-stent restenosis after Wingspan stenting is technically safe and feasible. However, selection criteria of patients and efficacy of a larger sample study will be needed.